Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer

Nearly all prostate cancers start out as adenocarcinomas driven by the androgen receptor (AR). Neuroendocrine prostate cancer (NEPC) is a rare, AR-independent subtype with a poor prognosis and limited treatment options. Importantly, because of the widespread use of novel AR-targeting agents, the inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Turina, Claire B, Coleman, Daniel J, Thomas, George V, Fung, Alice W, Alumkal, Joshi J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758987/
https://www.ncbi.nlm.nih.gov/pubmed/31565603
http://dx.doi.org/10.7759/cureus.5197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758987/
https://www.ncbi.nlm.nih.gov/pubmed/31565603
http://dx.doi.org/10.7759/cureus.5197

Ejemplares similares